Does varenicline promote abstinence in youths who vape?
Abstract
ABSTRACT Introduction Vapes are the most used tobacco product by school children in the U.S.A. Vaping commonly leads to combustible cigarette smoking, marijuana use, and initiation of other drugs of abuse. Consequently, ways to help youths stop vaping are required. Area covered The varenicline for nicotine vaping cessation in adolescents (ViVA) clinical trial was of varenicline in youths using vapes but not smoking cigarettes. Adding varenicline to behavioral counseling significantly increased the abstinence rate from 14% to 51% at 12 weeks. The efficacy of varenicline reduced through weeks 9–24 to 28%. Expert opinion More youths in the varenicline group than placebo group adhered to their medication and undertook counseling, and this may have biased the data toward higher abstinence in the varenicline group. The results of ViVA do not apply to adults, and those youths who are not actively seeking to stop vaping, and youths who smoke and are, probably, addicted to smoking/nicotine. Longer-term clinical trials in both youths and adults will be necessary to determine whether varenicline causes meaningful abstinence and is safe in long-term vaping.
Read the paper
Related studies
- Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary
- Comparative effects of e-cigarette smoking on periodontal status, salivary pH, and cotinine levels
- Association between exposure to environmental pollutants and increased oral health risks, a comprehensive review
- Influence of gestational window on offspring vascular health in rodents with in utero exposure to electronic cigarettes
- Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials
- Nicotine in electronic cigarettes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.